97 related articles for article (PubMed ID: 9755330)
1. Estimation of volume doubling time and cell loss in an experimental rat glioma model in vivo.
Nakajima M; Nakasu S; Morikawa S; Inubushi T
Acta Neurochir (Wien); 1998; 140(6):607-12; discussion 612-3. PubMed ID: 9755330
[TBL] [Abstract][Full Text] [Related]
2. Cell kinetic analysis of human brain tumors by in situ double labelling with bromodeoxyuridine and iododeoxyuridine.
Hoshino T; Ito S; Asai A; Shibuya M; Prados MD; Dodson BA; Davis RL; Wilson CB
Int J Cancer; 1992 Jan; 50(1):1-5. PubMed ID: 1728598
[TBL] [Abstract][Full Text] [Related]
3. Cell kinetics of rat 9L brain tumors determined by double labeling with iodo- and bromodeoxyuridine.
Asai A; Shibui S; Barker M; Vanderlaan M; Gray JW; Hoshino T
J Neurosurg; 1990 Aug; 73(2):254-8. PubMed ID: 2366082
[TBL] [Abstract][Full Text] [Related]
4. Cell kinetics of glial tumors.
Hoshino T
Rev Neurol (Paris); 1992; 148(6-7):396-401. PubMed ID: 1448658
[TBL] [Abstract][Full Text] [Related]
5. [Proliferation kinetics of human brain tumors by in situ double labeling with bromodeoxyuridine and iododeoxyuridine].
Maeda T; Hoshino T
No To Shinkei; 1992 Sep; 44(9):821-5. PubMed ID: 1476811
[TBL] [Abstract][Full Text] [Related]
6. Correlation of histopathological features and proliferative potential of gliomas.
Germano IM; Ito M; Cho KG; Hoshino T; Davis RL; Wilson CB
J Neurosurg; 1989 May; 70(5):701-6. PubMed ID: 2709110
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling.
Hoshino T; Ahn D; Prados MD; Lamborn K; Wilson CB
Int J Cancer; 1993 Feb; 53(4):550-5. PubMed ID: 8382191
[TBL] [Abstract][Full Text] [Related]
8. Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas.
Onda K; Davis RL; Shibuya M; Wilson CB; Hoshino T
Cancer; 1994 Oct; 74(7):1921-6. PubMed ID: 7521787
[TBL] [Abstract][Full Text] [Related]
9. A new method for analyzing the cell kinetics of human brain tumors by double labeling with bromodeoxyuridine in situ and with iododeoxyuridine in vitro.
Shibuya M; Ito S; Davis RL; Wilson CB; Hoshino T
Cancer; 1993 May; 71(10):3109-13. PubMed ID: 8490840
[TBL] [Abstract][Full Text] [Related]
10. Proliferative potential of recurrent intracranial meningiomas as evaluated by labelling indices of BUdR and Ki-67, and tumour doubling time.
Kakinuma K; Tanaka R; Onda K; Takahashi H
Acta Neurochir (Wien); 1998; 140(1):26-31; discussion 31-2. PubMed ID: 9522904
[TBL] [Abstract][Full Text] [Related]
11. Cell kinetics of human brain tumors: in vivo study with bromodeoxyuridine and flow cytometry.
Danova M; Riccardi A; Gaetani P; Wilson GD; Mazzini G; Brugnatelli S; Buttini R; Butti G; Ucci G; Paoletti P
Eur J Cancer Clin Oncol; 1988 May; 24(5):873-80. PubMed ID: 3169092
[TBL] [Abstract][Full Text] [Related]
12. [A review of cell kinetic studies on brain tumors with special reference to anti-bromodeoxyuridine monoclonal antibody method].
Nagashima T; Hoshino T
No Shinkei Geka; 1984 Aug; 12(9):1007-18. PubMed ID: 6390240
[TBL] [Abstract][Full Text] [Related]
13. Correlation between bromodeoxyuridine-labeling indices and patient prognosis in cerebral astrocytic tumors of adults.
Fujimaki T; Matsutani M; Nakamura O; Asai A; Funada N; Koike M; Segawa H; Aritake K; Fukushima T; Houjo S
Cancer; 1991 Mar; 67(6):1629-34. PubMed ID: 2001552
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of 201Tl SPECT in patients with glioma: a comparative study with histological diagnosis, clinical feature and proliferative activity].
Oriuchi N; Tamura M; Shibazaki T; Inoue T; Watanabe N; Tateno M; Tomiyoshi K; Hirano T; Igarashi H; Endo K
Kaku Igaku; 1991 Nov; 28(11):1263-71. PubMed ID: 1770641
[TBL] [Abstract][Full Text] [Related]
15. Flow-cytometric DNA analysis and immunohistochemical measurement of Ki-67 and BUdR labeling indices in human brain tumors.
Nishizaki T; Orita T; Furutani Y; Ikeyama Y; Aoki H; Sasaki K
J Neurosurg; 1989 Mar; 70(3):379-84. PubMed ID: 2536805
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of bromodeoxyuridine labeling in primary and recurrent glioblastoma multiforme.
Ritter AM; Sawaya R; Hess KR; Levin VA; Bruner JM
Neurosurgery; 1994 Aug; 35(2):192-8; discussion 198. PubMed ID: 7969825
[TBL] [Abstract][Full Text] [Related]
17. [Histopathologic changes and tumor cell kinetics after hyperthermia and/or radiation therapy in a rat glioma model: bromodeoxyuridine (BUdR) labelling index].
Tamura M; Tsukahara T; Kunimine H; Zama A; Tamaki Y; Niibe H
No Shinkei Geka; 1989 Jun; 17(6):555-9. PubMed ID: 2615905
[TBL] [Abstract][Full Text] [Related]
18. Cell kinetics in leukaemia and solid tumours studied with in vivo bromodeoxyuridine and flow cytometry.
Riccardi A; Danova M; Dionigi P; Gaetani P; Cebrelli T; Butti G; Mazzini G; Wilson G
Br J Cancer; 1989 Jun; 59(6):898-903. PubMed ID: 2736227
[TBL] [Abstract][Full Text] [Related]
19. Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas.
Zhen HN; Zhang X; Hu PZ; Yang TT; Fei Z; Zhang JN; Fu LA; He XS; Ma FC; Wang XL
Cancer; 2005 Dec; 104(12):2775-83. PubMed ID: 16284993
[TBL] [Abstract][Full Text] [Related]
20. Prediction of tumor doubling time in recurrent meningiomas. Cell kinetics studies with bromodeoxyuridine labeling.
Cho KG; Hoshino T; Nagashima T; Murovic JA; Wilson CB
J Neurosurg; 1986 Dec; 65(6):790-4. PubMed ID: 3772477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
